Information provided pursuant to § 24 of the Rules of the Warsaw Stock Exchange S.A.

Current report no. 13/2026

Drafting date: 31 March 2026

Subject: Information provided pursuant to § 24 of the Rules of the Warsaw Stock Exchange S.A.

Legal basis: Article 56(1)(2)(a) of the Act of 29 July 2005 on Public Offerings and the Conditions for Introducing Financial Instruments to Organised Trading, and on Public Companies.

The Management Board of Captor Therapeutics S.A., with its registered office in Wrocław (“the Company”, “Issuer”), acting pursuant to § 24 of the Rules of the Warsaw Stock Exchange (“WSE”), hereby announces the reasons for the failure to admit to trading, within 6 months of the end of the subscription period, 24,688 Series W ordinary bearer shares issued by the Company pursuant to the resolution of the Company’s Management Board of 25 August 2025 concerning the issue of Series W ordinary bearer shares within the limits of the Company’s authorised capital, with the pre-emptive rights of the Company’s existing shareholders being excluded in full, the adoption of which the Company announced in Current Report No. 34/2025 of 25 August 2025 (“Series W Shares”).

The subscription for Series W Shares closed on 30 September 2025, as announced by the Company in Current Report No. 48/2025 dated 14 October 2025.

The main reason for the failure to introduce Series W Shares to trading on the stock exchange by the aforementioned date was the protracted registration proceedings conducted by the registry court competent for the Issuer’s registered office, concerning the registration of the increase in the Company’s share capital and the amendment of the Company’s Articles of Association. This registration took place on 22 January 2026, as announced by the Company in Current Report No. 2/2026 of 22 January 2026.

The Company also announces that it has already submitted the relevant applications to the National Depository for Securities S.A. and the Warsaw Stock Exchange and is currently seeking the earliest possible admission and listing of Series W Shares for trading on the WSE’s main market.